Lusutrombopag

DB13125ApprovedInvestigationalSmall moleculeThrombopoietin Receptor Agonist

Lusutrombopag is a medication used to treat thrombocytopenia in patients with chronic liver disease scheduled to have a procedure. Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan).

Chemical structure of Lusutrombopag
Mechanism
Curator reviewed · 5 references
Primary indication
Lusutrombopag is indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.Curator reviewed · 1 structured indication
Formula / weight
C29H32Cl2N2O5S · 591.54 g/mol (avg)
First approval
United States, 2018
Code names
S-888711
Brand names
  • Mulpleta

Resolves to

Structure
InChIKeyNOZIJMHMKORZBA-KJCUYJGMSA-NSMILESCCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C2)=N1
Targets

What you can answer from here — as of March 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
305Drug interactionsStructured to mechanism, not free text
Sign in
8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
4Marketed productsAcross 2 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 7 drug categories
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lusutrombopag, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account